Partner with Foresight to access
MRD assays that rise above the noise.

The Challenge

Existing MRD assays lack sensitivity when disease burden is low.

The highest resolution SNV-based liquid biopsies are still unable to confidently differentiate cured cases from relapsing cases when disease burden is low. Spontaneous and benign SNVs occur frequently enough to obscure the scant presence of tumor-associated SNVs. The inherent error rate of NGS-based testing can further mask low-allelic frequency ctDNA mutations. This background noise results in missed relapses hiding in plain sight.

Our Solution

PVphased variant (i.e. multiple SNVs) SNVsingle nucleotide variant vs mutational signal : noise ctDNA

Phased variants are the best-in-class approach to ctDNA monitoring.

Single nucleotide variations are common and counting them can be inconclusive due to the inherent error rates of NGS. But multiple SNVs found on a short sequencing read (a.k.a. phased variants, or PVs) can be uniquely attributed to malignant cells. PVs commonly occur in all types of cancers, and by specifically monitoring tumor-specific PVs, we have attained unmatched MRD sensitivity.

By leveraging this untapped biology in cancers, we’re able to identify MRD at levels below the detection limit of conventional NGS-based ctDNA assays. We cut the noise that leading error suppression methods like duplex sequencing and barcoding can’t.

Personalized analysis without personalized panels.

Personalized analysis without personalized panels.

Our proprietary assays detect MRD across liquid and solid tumors with unprecedented sensitivity and specificity.

In lymphoma and other blood cancers, validated mutational signatures eliminate the need for customized assays, expediting MRD-guided research and treatment with personalized analysis, from off-the-shelf panels.

Unprecedented clarity
at every step of treatment.

Lymphoma & Blood Cancers

Treatment
Start

Unlike personalized MRD assays that require exome sequencing and patient-specific panel design, Foresight’s Lymphoma Recurrence Test is an off-the-shelf panel that can be used to measure extremely low amounts of ctDNA from plasma, giving up to 100X improved sensitivity of cancer detection that results in identifying recurrence an average of 200 days earlier* than conventional methods.

Diagnosis /
Trial Enrollment

Compare germline DNA with pre-treatment plasma DNA for personalized PV genotyping via targeted sequencing.

No tumor sample needed for assay personalization.

Treatment
PROGRESS

Mid- and end-of-treatment plasma ctDNA assayed for MRD assessment.
Treatment plan is informed by ctDNA levels.

Treatment
END

Post-Treatment
MONITORING

Post-treatment plasma DNA assayed for longitudinal cancer surveillance.

check mark

No tumor samples or customization needed

check mark

Assays performed at our CLIA-certified lab

More About Lymphoma Recurrence Test

solid tumors Solid Tumors

Our Solid Tumor Recurrence Test is personalized based on patient-specific phased variants that are identified with whole-genome sequencing. It offers the same degree of sensitivity as our Lymphoma Recurrence Test and the ability to track oncogenic and clinically relevant SNVs in addition to other tumor-specific phased variants.

More About Solid Tumor Recurrence Test

partnering options

CLIA assay

Screen less patients and complete recruitment faster.

Within the same patient population, there are twice as many participants eligible to enroll your MRD-driven trial than you think. Foresight’s method detects ultra-low ctDNA levels undetectable by existing liquid biopsies. We capture the false-negatives others missed. Get the full picture of all the patients who need treatment.

CLIA Assay
MRD-driven clinical trials

Use MRD status to enroll patients into a clinical trial.

Companion diagnostic development

Use the Foresight MRD testing platform to enrich patient populations for those with the highest likelihood of responding to a given therapy

MRD as an exploratory endpoint

Assess MRD over the course of a treatment regimen to quantify depth of response.

MRD as a surrogate endpoint

Accelerate trial completion by using MRD negativity as surrogate endpoint.

research assay

One assay.
Many applications.

Our ctDNA testing platform is also available outside of our CLIA lab as a research assay, and can answer a wide variety of pressing questions in translational research. Quantify and monitor disease burden over time in both solid tumors and blood cancers.

Rsearch Assay
Genotyping

Understand mechanisms of response or resistance.

Precision / personalized medicine

Identify actionable mutations for targeted treatments. Classify patients into genotypically-defined molecular subtypes, including cell of origin determination for DLBCL.

Relapse detection

Identify recurrent disease when ctDNA levels are up to 100x below the limits of existing MRD assays.

Patient stratification

Separate responders from non-responders based on genotype, mutational status, or changes in disease burden.

Meet our team right arrow Contact Us right arrow